Buyer’s Guide: How to Choose an Imaging CRO Partner and Clinical Trial Imaging Platform

Selecting the right imaging platform and imaging CRO (iCRO) can be the difference between “images collected” and “decisions made early and with confidence.” For mid‑size biotechs and pharma, this choice is even more critical, as every scan and every visit must work harder to de‑risk the asset and support regulatory‑grade clinical evidence.

In this buyer’s guide, we outline what to look for in a clinical trial imaging platform and imaging CRO partner, and how DYNAMIKA™, IAG’s Imaging Control Platform, helps sponsors run quantitative, AI‑enabled imaging trials efficiently and compliantly.

Imaging endpoints increasingly drive go/no‑go decisions, dose selection, and regulatory narratives across oncology, rheumatology, cardiology, liver and metabolic disease, and rare indications. Yet many sponsors still rely on generic workflows and fragmented vendor ecosystems that were never designed for quantitative, AI‑enabled imaging analysis in clinical trials.

Common challenges we hear from mid‑size sponsors include:

1. Limited visibility into imaging readiness and data quality until late in the trial
2. Batch delivery of imaging reads that slows decision‑making and interim analyses
3. Manual, error‑prone handoffs between systems for upload, QC, reads, and analysis
4. Difficulty validating AI tools and quantitative imaging biomarkers in a compliant way

An effective imaging strategy requires more than a traditional imaging core lab. It needs a purpose‑built imaging operating system that connects protocol, sites, QC, reads, and data delivery into one controlled pipeline.

When you evaluate clinical trial imaging platforms, focus on the control layer that will run your trial, not just the viewer or reading interface. The right platform will orchestrate the entire imaging data pipeline and make quantitative imaging and AI‑enabled workflows practical at scale.

A modern clinical trial imaging platform should:

• Orchestrate acquisition guidance, site uploads, de‑identification, QC, central reads, quantitative analysis, and regulatory‑ready data exports from a single environment
• Track imaging status at patient, site, and study level to support real‑time decision‑making
• Reduce reliance on email, spreadsheets, and disconnected portals

This end‑to‑end control is essential for imaging‑heavy trials where delays or errors in the pipeline can impact recruitment, database lock, and submission timelines.

For sponsors planning quantitative studies or exploring imaging biomarkers, the platform must be built for advanced analysis:

• Support for complex, multi‑parametric imaging (DCE‑MRI, MRI‑PDFF, fat fraction, volumetrics, and other quantitative endpoints)
• Seamless integration of validated AI tools for segmentation, lesion quantification, and biomarker extraction
• Full traceability and auditability of AI outputs, including versions, parameters, and readers’ interactions

This architecture lets teams scale quantitative imaging and AI‑assisted workflows without sacrificing compliance.

Rather than waiting for periodic batch exports, your teams should have near real‑time visibility into:

• Image availability and site performance
• QC and reading status for each subject and time point
• Extracted metrics and endpoint readiness

Continuous data availability supports adaptive designs, early signal detection, and faster internal decisions on dosing, expansion cohorts, or program direction.

Regulators expect robust controls around imaging data. When assessing a clinical trial imaging platform, check that it is:

• Developed under ISO 13485 or equivalent quality management framework
• Aligned with 21 CFR Part 11 and Good Clinical Practice requirements for electronic records and signatures
• Supported by SOC II‑aligned security practices and detailed audit trails for every change, read, and approval

Compliance cannot be an add‑on; it must be built into the platform from day one.

Each protocol and indication is different. Your imaging platform should allow:

• Configurable reading forms, scoring systems, and report templates
• Support for indication‑specific scoring, such as K&L grading in osteoarthritis, MRI‑PDFF in NASH, or fat fraction in neuromuscular disease
• Study‑specific rules for eligibility, endpoint definitions, and data export

Configurable workflows reduce the need for custom development and help teams standardise successful designs across multiple trials.

Technology alone is not enough; the platform must be operated by an imaging CRO partner that understands your therapeutic area and treats your study as a priority. The best results come when a specialist imaging CRO combines therapeutic‑area expertise with a purpose‑built clinical trial imaging platform.

Your iCRO should bring deep experience with:

• Imaging endpoints and biomarkers in your indication
• Regulatory interactions, including how imaging is positioned in submissions
• The specific modalities and sequences used in your protocol

Ask for case examples that demonstrate how the team has applied advanced imaging endpoints in similar studies and how those readouts influenced development decisions.

The most efficient model is when the iCRO runs all operations on its own validated imaging platform, acting as the “operating system” for trial imaging.

This integration enables:

• Faster study set‑up and mid‑study adjustments
• Consistent workflows from site to submission
• Single‑source accountability for imaging quality and timelines

An integrated imaging platform and iCRO service model also simplifies vendor oversight for your clinical operations, data management, and QA teams.

For mid‑size sponsors, you need an iCRO that is accountable for study outcomes, not just for delivering reads against a generic SOP.

Look for:

• Proactive monitoring of imaging risk, such as site performance and data completeness
• Regular, interpretable dashboards on imaging readiness and endpoint status
• Willingness to refine imaging strategy as the trial progresses

This study‑level accountability ensures that imaging remains aligned with the scientific, operational, and commercial goals of the program.

Strong outcomes start with strong sites.

Your iCRO should provide:

• Clear acquisition guidelines and protocol‑specific imaging manuals
• Site onboarding and training directly supported by the clinical trial imaging platform
• Easy upload workflows, automated QC, and rapid feedback loops

These capabilities help sites deliver consistent imaging data with minimal friction, fewer repeat scans, and reduced burden on investigators and coordinators.

The right imaging CRO partner will maintain strategic collaborations. For example, with AI innovators, cardiac safety providers, or specialty imaging vendors, to offer integrated workflows without multiplying your vendor list. This ecosystem approach gives sponsors access to cutting‑edge AI‑enabled imaging analysis and safety solutions within a controlled and compliant framework.

IAG has built DYNAMIKA™ as the Imaging Control Platform that underpins every clinical trial we run, effectively serving as the “operating system” for imaging‑heavy and biomarker‑driven clinical research.

Through DYNAMIKA™, we:

• Encode protocols, imaging parameters, and quantitative models directly into study‑specific workflows, ensuring that every scan is acquired, QC‑checked, and analysed in line with how it will be interpreted
• Provide continuous QC and central reads, with real‑time visibility into imaging readiness, so sponsors always know how much usable imaging data they have today – not weeks later
• Integrate AI tools from a curated ecosystem of partners, enabling AI‑assisted lesion segmentation, volumetrics, and biomarker extraction within a compliant, auditable framework
• Deliver regulator‑ready datasets with full traceability from raw images to final endpoints, supporting submissions across oncology, rheumatology, metabolic disease, rare diseases, and more

For mid‑size biotechs and pharma running imaging‑heavy or biomarker‑driven studies, this combination of specialist imaging CRO services and a purpose‑built clinical trial imaging platform turns imaging from a logistical burden into a strategic advantage.

When you compare options, ask whether the imaging platform and imaging CRO partner can reliably turn images into structured, quantitative data that de‑risks your program. Not just complete another read.

For mid‑size sponsors, IAG finds the winning combination is:

• A therapeutic‑area‑specialized iCRO
• Operating on a validated, quantitative, AI‑ready clinical trial imaging platform
• Delivering more signal per image, sooner in the trial

If you are planning an imaging‑heavy or biomarker‑driven study and want to see how DYNAMIKA™ and IAG could support your program…

Contact our team today to discuss your next clinical trial: contact@www.ia-grp.com.